Testing a new inhaled treatment for cystic fibrosis lung infections

Plain-English translation of NCT06998043 on ClinicalTrials.gov ↗ · Source last updated July 2025 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing , a new inhaled treatment made from bacteriophages—tiny viruses that are designed to target and reduce harmful pseudomonas bacteria in the lungs of people with cystic fibrosis. The medication is inhaled as a mist, similar to other CF breathing treatments you may already use. Researchers want to see if this treatment can reduce the bacterial burden in your lungs and help improve your breathing and quality of life.

Pseudomonas is a stubborn bacteria that commonly infects the lungs of people with cystic fibrosis and can be difficult to treat with standard antibiotics alone. This medication offers a new approach by using bacteriophages to attack the bacteria in a different way, potentially helping patients who have ongoing infections despite current treatments.

Do you qualify?

You likely qualify if…

you have cystic fibrosis with a confirmed chronic pseudomonas lung infection
you are at least 18 years old
your lung function is between 40% and 80% of predicted (measured by a breathing test called FEV1)
your cystic fibrosis lung disease is currently stable
you are able to provide sputum (mucus) samples at study visits, either by coughing them up naturally or through other methods

You likely don't qualify if…

you have a known allergy or sensitivity to bacteriophages
you have received bacteriophage therapy within the past 6 months
you have a history of lung transplant or other organ transplant
you are pregnant or breastfeeding
you have been diagnosed with certain other serious lung infections (like Burkholderia or Mycobacterium abscessus) within the past year

What participation looks like

You will visit the clinic regularly over several months to inhale either the new medication or a placebo (a dummy treatment with no active ingredient)—you won't know which one you're receiving, and neither will the study team. During visits, you'll provide sputum samples, have breathing tests, and answer questions about how you're feeling. The study includes a 6-month safety follow-up period after you finish receiving the treatment to make sure everything is going well.

AI-generated summary from trial data · Jun 5, 2026 · Not medical advice

Trial locations(14 sites)

United States

University of Alabama at Birmingham, Birmingham, Alabama

Providence Alaska Medical Center, Anchorage, Alaska

University of Arkansas for Medical Sciences, Little Rock, Arkansas

Stanford University, Palo Alto, California

University of California San Francisco, San Francisco, California